...
首页> 外文期刊>Cell death & disease. >The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation
【24h】

The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation

机译:趋化因子受体CCR10通过PI3K / Akt途径激活促进炎症驱动的肝癌发生

获取原文
           

摘要

G-protein-coupled receptor (GPCR)-related proteins are dysregulated and the GPCR CC-chemokine receptor 10 (CCR10) is significantly upregulated in inflammation-driven HCC. However, CCR10′s role in inflammation-driven hepatocarcinogenesis remains unknown. The aim of this study was to evaluate the role of CCR10 in inflammation-driven hepatocarcinogenesis. Via a targeted gene expression microarray screening alterations in GPCR family gene expression, we found CCR10 to be significantly upregulated in hepatocytes isolated from inflammation-driven human HCC tumors and matching paracancerous tissues. Tetrachloromethane (CCl4)-induced and diethylnitrosamine (DEN)-induced murine models of inflammatory hepatocarcinogenesis displayed significant hepatocellular TNF and CCR10 upregulation. Exogenous TNF applied to HepG2 and LO2 cell lines as well as wild-type (WT) mice significantly upregulated hepatocellular CCR10 expression, Akt phosphorylation, PCNA expression, and hepatocellular proliferation. Additionally, exogenous TNF significantly upregulated secretion of the natural CCR10 ligand-agonist CCL28 from both cell lines. Transgenic CCR10-knockout (CCR10 KO) in DEN-treated mice significantly increased hepatocellular apoptosis levels and significantly lowered compensatory hepatocellular proliferation but did not affect upstream TNF expression. In addition, DEN-treated CCR10 KO mice showed a significantly lower liver weight/body weight ratio, significantly lower liver tumor incidence, and significantly smaller tumors. Moreover, exogenous CCR10 expression significantly raised xenograft tumor growth in Balb/c nude mice. In vitro, CCR10 transfection or CCL28 treatment in HepG2 and LO2 cell lines significantly increased Akt phosphorylation, PCNA expression, and cell proliferation, while CCR10 silencing or Akt inhibition produced the opposite effects. In vivo, hepatocytes isolated from HCC tumor tissue and matching paracancerous tissue in DEN-treated CCR10 KO mice showed significantly lower Akt phosphorylation and PCNA expression relative to WT hepatocytes. In conclusion, inflammation-induced TNF promotes hepatocellular CCR10 expression and downstream PI3K/Akt-mediated hepatocarcinogenesis. CCR10 appears to function as a linkage between TNF stimulation and downstream PI3K/Akt pathway activation and shows promise as a potential therapeutic target for inflammation-driven HCC.
机译:G蛋白偶联受体(GPCR)相关蛋白失调,而GPCR CC趋化因子受体10(CCR10)在炎症驱动的HCC中显着上调。然而,CCR10在炎症驱动的肝癌发生中的作用仍然未知。这项研究的目的是评估CCR10在炎症驱动的肝癌发生中的作用。通过靶向基因表达微阵列筛选GPCR家族基因表达的变化,我们发现从炎症驱动的人类HCC肿瘤和匹配的癌旁组织分离的肝细胞中CCR10明显上调。四氯甲烷(CCl4)诱导和二乙基亚硝胺(DEN)诱导的小鼠炎症性肝癌发生模型表现出明显的肝细胞TNF和CCR10上调。应用于HepG2和LO2细胞系以及野生型(WT)小鼠的外源性TNF显着上调了肝细胞CCR10表达,Akt磷酸化,PCNA表达和肝细胞增殖。另外,外源性TNF显着上调了两种细胞系中天然CCR10配体-激动剂CCL28的分泌。 DEN处理的小鼠中的转基因CCR10基因敲除(CCR10 KO)显着增加了肝细胞凋亡水平,并显着降低了代偿性肝细胞增殖,但并未影响上游TNF的表达。另外,用DEN治疗的CCR10 KO小鼠显示出显着降低的肝重/体重比,显着降低的肝肿瘤发生率和显着小的肿瘤。此外,外源CCR10表达显着提高了Balb / c裸鼠的异种移植肿瘤的生长。在体外,在HepG2和LO2细胞系中进行CCR10转染或CCL28处理可显着增加Akt磷酸化,PCNA表达和细胞增殖,而CCR10沉默或Akt抑制则产生相反的作用。在体内,与WT肝细胞相比,在DEN治疗的CCR10 KO小鼠中从HCC肿瘤组织和匹配的癌旁组织分离的肝细胞显示出明显较低的Akt磷酸化和PCNA表达。总之,炎症诱导的TNF促进肝细胞CCR10表达和下游PI3K / Akt介导的肝癌发生。 CCR10似乎是TNF刺激和下游PI3K / Akt途径激活之间的联系,并有望作为炎症驱动的HCC的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号